LU

Lucyd, Inc

LUCYHealthcareNASDAQ

Medical Instruments & Supplies

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.7M
+62.6% YoY
Net Income
-$7.6M
+2.3% YoY
EBITDA
-$8.4M
-7.5% YoY
Free Cash Flow
-$5.4M

Scan Results

Daily timeframe
DateIndicatorDetails
Oct 20CONFIRMED▲ RSI OversoldRSI 25.9, below 30, stock may be oversold
Oct 19CONFIRMED▲ RSI OversoldRSI 20.9, below 30, stock may be oversold
About Lucyd, Inc

Lucyd, Inc develops and sells smart eyewear in North America. The $7.6M market capitalization puts LUCY squarely in micro-cap range for its industry. It offers smart eyewear products to enable wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform smartphone tasks hands-free, as well as prescription eyeglasses, ready-to-wear sunglasses, safety glasses, and sport glasses under the Lucyd Lyte, Lucyd Armor, Nautica, Eddie Bauer, and Reebok brand names.

Where LUCY stands vs its 150-day and 200-day moving averages

As of the October 20, 2026 close, LUCY finished 13.04% below its 150-day moving average ($0.92) and 20.00% below its 200-day moving average ($1.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is LUCY overbought or oversold?

At the October 20, 2026 close, LUCY's RSI(14) was 25.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$7.6M
Fwd P/E-2.06
EPS$-1.29
Beta2.74
52W Change-51.8%
Dividend Yield0.00%
ROE-84.6%
Analysis

Lucyd, Inc reports $3.7M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$5.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -84.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $660K (2022) to $2.7M (2025), reflecting a 303% increase over the period.

With a beta above 1.5, LUCY tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Lucyd, Inc's trajectory.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms